UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

SAR and in vivo evaluation of 4-aryl-2-aminoalkylpyrimidines as potent and selective Janus kinase 2 (JAK2) inhibitors

Bioorganic & medicinal chemistry letters, 2012-12, Vol.22 (24), p.7653-7658

2012

Volltextzugriff (PDF)

Required Immunoproteasome Subunit Inhibition Profile for Anti-Inflammatory Efficacy and Clinical Candidate KZR-616 ((2S,3R)‑N‑((S)‑3-(Cyclopent-1-en-1-yl)-1-((R)‑2-methyloxiran-2-yl)-1-oxopropan-2-yl)-3-hydroxy-3-(4-methoxyphenyl)-2-((S)‑2-(2-morpholinoacetamido)propanamido)propenamide)

Journal of medicinal chemistry, 2018-12, Vol.61 (24), p.11127-11143

2018

Volltextzugriff (PDF)

Co-inhibition of immunoproteasome subunits LMP2 and LMP7 enables prevention of transplant arteriosclerosis

Cardiovascular research, 2023-05, Vol.119 (4), p.1030-1045

2023

Volltextzugriff (PDF)

Abstract 2226: Prioritizing tumor types for clinical study of novel Sec61 inhibitors by searching for expression profiles of sensitive cell lines in tumor sample databases

Cancer research (Chicago, Ill.), 2021-07, Vol.81 (13_Supplement), p.2226-2226

2021

Volltextzugriff (PDF)

Proteomic Profiling and Mechanistic Investigating of a Novel Anti-Cancer Small Molecule Inhibitor of Sec61

Blood, 2019-11, Vol.134 (Supplement_1), p.2076-2076

2019

Volltextzugriff (PDF)

Blocking Protein Secretion with Novel Small Molecule Inhibitors of Sec61 Represents a Potential Treatment Strategy Against Hematologic Malignancies

Blood, 2019-11, Vol.134 (Supplement_1), p.408-408

2019

Volltextzugriff (PDF)

Zetomipzomib (KZR-616) attenuates lupus in mice via modulation of innate and adaptive immune responses

Frontiers in immunology, 2023-03, Vol.14, p.1043680-1043680

2023

Volltextzugriff (PDF)

Discovery of a Novel Class of Highly Potent, Selective, ATP-Competitive, and Orally Bioavailable Inhibitors of the Mammalian Target of Rapamycin (mTOR)

Journal of medicinal chemistry, 2013-03, Vol.56 (6), p.2218-2234

2013

Volltextzugriff (PDF)

Discovery of Highly Selective Inhibitors of the Immunoproteasome Low Molecular Mass Polypeptide 2 (LMP2) Subunit

ACS medicinal chemistry letters, 2017-04, Vol.8 (4), p.413-417

2017

Volltextzugriff (PDF)

Discovery of a Novel Series of Potent and Orally Bioavailable Phosphoinositide 3-Kinase γ Inhibitors

Journal of medicinal chemistry, 2012-06, Vol.55 (11), p.5467-5482

2012

Volltextzugriff (PDF)

A Polyether Biotoxin Binding Site on the Lipid-Exposed Face of the Pore Domain of KV Channels Revealed by the Marine Toxin Gambierol

Proceedings of the National Academy of Sciences - PNAS, 2009-06, Vol.106 (24), p.9896-9901

2009

Volltextzugriff (PDF)

The Total Synthesis of Gambierol

Journal of the American Chemical Society, 2005-01, Vol.127 (3), p.848-849

2005

Volltextzugriff (PDF)

Total Synthesis of Gambierol: The Generation of the A-C and F-H Subunits by Using a C-Glycoside Centered Strategy

Chemistry : a European journal, 2006-02, Vol.12 (6), p.1736-1746

2006

Volltextzugriff (PDF)

Total Synthesis of Gambierol: Subunit Coupling and Completion

Chemistry : a European journal, 2006-02, Vol.12 (6), p.1747-1753

2006

Volltextzugriff (PDF)

Discovery of a Novel Class of Potent and Orally Bioavailable Sphingosine 1-Phosphate Receptor 1 Antagonists

Journal of medicinal chemistry, 2012-02, Vol.55 (3), p.1368-1381

2012

Volltextzugriff (PDF)

C-Glycosides to fused polycyclic ethers

Tetrahedron, 2002-03, Vol.58 (10), p.1997-2009

2002

Volltextzugriff (PDF)

1 – 16 von 16

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(16)
Mit Volltextzugriff
(16)

Publikationsform

Artikel
(16)

Sprache

Englisch
(16)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

SAR and in vivo evaluation of 4-aryl-2-aminoalkylpyrimidines as potent and selective Janus kinase 2 (JAK2) inhibitors

Required Immunoproteasome Subunit Inhibition Profile for Anti-Inflammatory Efficacy and Clinical Candidate KZR-616 ((2S,3R)‑N‑((S)‑3-(Cyclopent-1-en-1-yl)-1-((R)‑2-methyloxiran-2-yl)-1-oxopropan-2-yl)-3-hydroxy-3-(4-methoxyphenyl)-2-((S)‑2-(2-morpholinoacetamido)propanamido)propenamide)

Co-inhibition of immunoproteasome subunits LMP2 and LMP7 enables prevention of transplant arteriosclerosis

Abstract 2226: Prioritizing tumor types for clinical study of novel Sec61 inhibitors by searching for expression profiles of sensitive cell lines in tumor sample databases

Proteomic Profiling and Mechanistic Investigating of a Novel Anti-Cancer Small Molecule Inhibitor of Sec61

Blocking Protein Secretion with Novel Small Molecule Inhibitors of Sec61 Represents a Potential Treatment Strategy Against Hematologic Malignancies

Zetomipzomib (KZR-616) attenuates lupus in mice via modulation of innate and adaptive immune responses

Discovery of a Novel Class of Highly Potent, Selective, ATP-Competitive, and Orally Bioavailable Inhibitors of the Mammalian Target of Rapamycin (mTOR)

Discovery of Highly Selective Inhibitors of the Immunoproteasome Low Molecular Mass Polypeptide 2 (LMP2) Subunit

Discovery of a Novel Series of Potent and Orally Bioavailable Phosphoinositide 3-Kinase γ Inhibitors

A Polyether Biotoxin Binding Site on the Lipid-Exposed Face of the Pore Domain of KV Channels Revealed by the Marine Toxin Gambierol

The Total Synthesis of Gambierol

Total Synthesis of Gambierol: The Generation of the A-C and F-H Subunits by Using a C-Glycoside Centered Strategy

Total Synthesis of Gambierol: Subunit Coupling and Completion

Discovery of a Novel Class of Potent and Orally Bioavailable Sphingosine 1-Phosphate Receptor 1 Antagonists

C-Glycosides to fused polycyclic ethers

Suchergebnisse filtern